AzureCell bioengineers next generation allogeneic iPSC-derived neuron replacement therapies for neurodegenerative diseases. By integrating precise neuronal differentiation with programmable genetic circuits, the company develops living therapies that rebuild damaged brain circuitry while actively counteracting disease drivers. The platform targets durable, disease modifying outcomes, starting with Parkinson’s disease.
NAGOSHI Emi, SAB Chair
